Kai Pinkernell

Kai Pinkernell

Company: glycostem

Job title: Chief Medical Officer


Examining Data from NK Cell Therapy to Assess Therapeutic Efficacy, and Preclinical Findings from CAR-NK Cells 8:45 am

Discussing if results indicate the potential for NK cell therapy to prolong event-free survival in patients, and the implications for treatment regimens Considering the requirement for multiple infusions based on preliminary clinical results Examining unpublished preclinical data from CAR-NK constructsRead more

day: Day Two

Chair’s Opening Remarks 8:00 am

Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.